{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T07:07:18Z","timestamp":1715670438671},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40801-019-0154-4","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T17:05:38Z","timestamp":1556903138000},"page":"83-91","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab"],"prefix":"10.1007","volume":"6","author":[{"given":"Marina","family":"Magrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bozyczko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Wolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Mordin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costel","family":"Chirila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"key":"154_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53:650\u20137.","journal-title":"Global prevalence of ankylosing spondylitis. Rheumatology (Oxford)"},{"key":"154_CR2","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127\u201337.","journal-title":"Lancet"},{"key":"154_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1148\/radiol.10100426","volume":"258","author":"JH Jang","year":"2011","unstructured":"Jang JH, Ward MM, Rucker AN, et al. Ankylosing spondylitis: patterns of radiographic involvement: a re-examination of accepted principles in a cohort of 769 patients. Radiology. 2011;258:192\u20138.","journal-title":"Radiology"},{"key":"154_CR4","doi-asserted-by":"publisher","first-page":"268569","DOI":"10.1155\/2009\/268569","volume":"2009","author":"J Oldroyd","year":"2009","unstructured":"Oldroyd J, Schachna L, Buchbinder R, et al. Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database. Int J Rheumatol. 2009;2009:268569.","journal-title":"Int J Rheumatol"},{"key":"154_CR5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/ard.2009.116178","volume":"69","author":"JH Kang","year":"2010","unstructured":"Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis. 2010;69:1165\u20138.","journal-title":"Ann Rheum Dis"},{"key":"154_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/acr.20408","volume":"63","author":"A Bremander","year":"2011","unstructured":"Bremander A, Petersson IF, Bergman S, et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken). 2011;63:550\u20136.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"154_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3899\/jrheum.150388","volume":"43","author":"CC Shen","year":"2016","unstructured":"Shen CC, Hu LY, Yang AC, et al. Risk of psychiatric disorders following ankylosing spondylitis: a nationwide population-based retrospective cohort study. J Rheumatol. 2016;43:625\u201331.","journal-title":"J Rheumatol"},{"key":"154_CR8","doi-asserted-by":"publisher","first-page":"e94027","DOI":"10.1371\/journal.pone.0094027","volume":"9","author":"CW Lin","year":"2014","unstructured":"Lin CW, Huang YP, Chiu YH, et al. Increased risk of ischemic stroke in young patients with ankylosing spondylitis: a population-based longitudinal follow-up study. PLoS One. 2014;9:e94027.","journal-title":"PLoS One"},{"key":"154_CR9","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han C, Robinson DWJ, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167\u201372.","journal-title":"J Rheumatol"},{"key":"154_CR10","first-page":"4","volume":"78","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4\u201311.","journal-title":"J Rheumatol Suppl"},{"key":"154_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391.","journal-title":"Ann Rheum Dis"},{"key":"154_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2016;68:282\u201398.","journal-title":"Arthritis Rheumatol"},{"key":"154_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10238-014-0323-4","volume":"15","author":"N Maruotti","year":"2015","unstructured":"Maruotti N, d\u2019Onofrio F, Cantatore FP. Metabolic syndrome and chronic arthritis: effects of anti-TNF-\u03b1 therapy. Clin Exp Med. 2015;15:433\u20138.","journal-title":"Clin Exp Med"},{"key":"154_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896\u2013904.","journal-title":"Ann Rheum Dis"},{"key":"154_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/art.38291","volume":"66","author":"JA Smith","year":"2014","unstructured":"Smith JA, Colbert RA. The interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: th17 and beyond. Arthritis Rheumatol. 2014;66:231\u201341.","journal-title":"Arthritis Rheumatol"},{"key":"154_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","volume":"33","author":"L Xueyi","year":"2013","unstructured":"Xueyi L, Lina C, Zhenbiao W, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-\u03b1 therapy. J Clin Immunol. 2013;33:151\u201361.","journal-title":"J Clin Immunol"},{"key":"154_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","volume":"19","author":"SP Raychaudhuri","year":"2017","unstructured":"Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther. 2017;19:51.","journal-title":"Arthritis Res Ther"},{"key":"154_CR18","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60:1647\u201356.","journal-title":"Arthritis Rheum"},{"key":"154_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t\u2009+\u2009CD3\u2009+\u2009CD4-CD8- entheseal resident T cells. Nature Med. 2012;18:1069\u201376.","journal-title":"Nature Med"},{"key":"154_CR20","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","volume":"186","author":"P Bowness","year":"2011","unstructured":"Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2\u2009+\u2009and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011;186:2672\u201380.","journal-title":"J Immunol"},{"key":"154_CR21","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13:R95.","journal-title":"Arthritis Res Ther"},{"key":"154_CR22","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/art.33507","volume":"64","author":"TJ Kenna","year":"2012","unstructured":"Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64:1420\u20139.","journal-title":"Arthritis Rheum"},{"key":"154_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/art.33396","volume":"64","author":"T Noordenbos","year":"2012","unstructured":"Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cell contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64:99\u2013109.","journal-title":"Arthritis Rheum"},{"key":"154_CR24","unstructured":"Cosentyx (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation 2018."},{"key":"154_CR25","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A Inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348.","journal-title":"N Engl J Med"},{"key":"154_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"19","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19:285.","journal-title":"Arthritis Res Ther"},{"key":"154_CR27","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2147\/TCRM.S100091","volume":"12","author":"E Lubrano","year":"2016","unstructured":"Lubrano E, Perrotta FM. Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag. 2016;12:1587\u201392.","journal-title":"Ther Clin Risk Manag"},{"key":"154_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3\u201317.","journal-title":"Ann Rheum Dis"},{"key":"154_CR29","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281\u20135.","journal-title":"J Rheumatol"},{"key":"154_CR30","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"154_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3899\/jrheum.160411","volume":"45","author":"LE Dean","year":"2018","unstructured":"Dean LE, Macfarlane GJ, Jones GT. Five potentially modifiable factors predict poor quality of life in ankylosing spondylitis: results from the Scotland Registry for Ankylosing Spondylitis. J Rheumatol. 2018;45:62\u20139.","journal-title":"J Rheumatol"},{"key":"154_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/PPA.S121032","volume":"11","author":"SC Bolge","year":"2017","unstructured":"Bolge SC, Eldridge HM, Lofland JH, et al. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn\u2019s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Prefer Adherence. 2017;11:661\u20139.","journal-title":"Patient Prefer Adherence"},{"key":"154_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.semarthrit.2012.06.002","volume":"42","author":"S Brophy","year":"2013","unstructured":"Brophy S, Davies H, Dennis MS, et al. Fatigue in ankylosing spondylitis: treatment should focus on pain management. Semin Arthritis Rheum. 2013;42:361\u20137.","journal-title":"Semin Arthritis Rheum"},{"key":"154_CR34","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136\u201346.","journal-title":"Arthritis Rheum"},{"key":"154_CR35","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402\u201312.","journal-title":"Arthritis Rheum"},{"key":"154_CR36","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582\u201391.","journal-title":"Arthritis Rheum"},{"key":"154_CR37","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1111\/jdv.14468","volume":"32","author":"JR Georgakopoulos","year":"2018","unstructured":"Georgakopoulos JR, Ighani A, Zhou LL, et al. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol. 2018;32:e32\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"154_CR38","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/1346-8138.14145","volume":"45","author":"M Momose","year":"2018","unstructured":"Momose M, Asahina A, Umezawa Y, et al. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: a single-center experience. J Dermatol. 2018;45:318\u201321.","journal-title":"J Dermatol"},{"key":"154_CR39","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/annrheumdis-2018-213055","volume":"77","author":"F Martinis","year":"2018","unstructured":"Martinis F, Caimmi C, Carletto A, et al. Real-world efficacy and safety of secukinumab: data from Verona\u2019s cohort. Ann Rheum Dis. 2018;77:1544\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"Key075","key":"154_CR40","first-page":"414","volume":"57","author":"J Robertson","year":"2018","unstructured":"Robertson J, Tindell A, Crosbie Stefan S. Real-world experience of secukinumab for psoriatic arthritis and axial spondyloarthritis. Rheumatology (Oxford). 2018;57(Key075):414.","journal-title":"Rheumatology (Oxford)"},{"key":"154_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"154_CR42","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1524-4733.2008.00323.x","volume":"11","author":"MA Ruiz","year":"2008","unstructured":"Ruiz MA, Pardo A, Rejas J, et al. Development and validation of the \u201cTREATMENT Satisfaction with Medicines Questionnaire\u201d (SATMED-Q). Value Health. 2008;11:913\u201326.","journal-title":"Value Health"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-019-0154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-019-0154-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-019-0154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T06:36:46Z","timestamp":1607582206000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-019-0154-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["154"],"URL":"https:\/\/doi.org\/10.1007\/s40801-019-0154-4","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"3 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Magrey served as a consultant for Novartis. M. Bozyczko has nothing to disclose. D. Wolin, M. Mordin, L. McLeod, E. Davenport, and C. Chirila are employees of RTI Health Solutions. Y. Park is an employee of Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"An institutional review board exemption was obtained for the study prior to initiation of data collection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained electronically from eligible patients interested in participating in this AS survey.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}